MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

(Z)-LFM-A13

CAS No. : 244240-24-2

MCE 国际站：(Z)-LFM-A13

产品活性：LFM-A13 是一种有效的 BTK，JAK2，PLK 抑制剂，可抑制 BTK，Plx1 和 PLK3 的活性，IC₅₀ 分别为 2.5 μM，10 μM 和 61 μM。

研究领域：Protein Tyrosine Kinase/RTK  |  Cell Cycle/DNA Damage  |  Epigenetics  |  Stem Cell/Wnt  |  JAK/STAT Signaling

作用靶点：Btk  |  Polo-like Kinase (PLK)  |  JAK

In Vitro: LFM-A13 significantly inhibits BTK activity with an IC₅₀ of 6.2 ± 0.3 μg/mL (= 17.2 ± 0.8 μM). The calculated K_is of LFM-A13 for BTK, JAK1, JAK3, IRK, EGFR and HCK are 1.4, 110, 148, 31.6, 166 and 214 μM. LFM-A13 (200 μM) markedly increases the chemosensitivity of ALL-1 cells to ceramide-induced apoptosis. LFM-A13 (100 μM) suppresses Epo-induced phosphorylation of EpoR, Jak2, Btk, Stat5 and Erk1/2 in R10 cells. LFM-A13 (100 μM) inhibits auto-phosphorylation of Jak2, Tec and Btk rather than Lyn kinase auto-phosphorylation in COS cells. LFM-A13 potently inhibits Plx1 with IC₅₀ of 10 μM; also inhibits BRK, BMX, FYN and with IC₅₀s of 267, 281, 240 and 215 μM.

In Vivo: LFM-A13 (25, 50 and 100 mg/kg) shows no apparent toxicity to rats. LFM-A13 (50 mg/kg, three times a week, i.p.) attenuates mammary tumorigenesis in mice. LFM-A13 alone or in combination with paclitaxel shows marked effect on the breast tumor incidence, mean tumor numbers, average tumor weight, and size in BALB/c mice. LFM-A13 (50 mg/kg, three times a week, i.p.) significantly decreases PLK1, cyclin D1, CDK-4, P53 and Bcl-2 expression, but increases the expression of p21, IκB, Bax and caspase 3 expression in mice. LFM-A13 (200 mg/kg) does not cause hematologic toxicity in rats. LFM-A13 (10 or 50 mg/kg, i.p.) exhibits anti-tumor effects dose dependently in the MMTV/Neu transgenic mouse model of breast cancer.

相关产品：Covalent Screening Library Plus  |  Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  Epigenetics Compound Library  |  Immunology/Inflammation Compound Library  |  JAK/STAT Compound Library  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Stem Cell Signaling Compound Library  |  Anti-Cancer Compound Library  |  Anti-Aging Compound Library  |  Covalent Screening Library  |  Differentiation Inducing Compound Library  |  Reprogramming Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Anti-Obesity Compound Library  |  Anti-Liver Cancer Compound Library   |  Anti-Prostate Cancer Compound Library  |  Cancer Stem Cells Compound Library  |  Membrane Protein-targeted Compound Library  |  AAPK-25  |  JAK-IN-20  |  Atuzabrutinib  |  JAK1-IN-9  |  AT9283  |  RO495  |  TK4b  |  TAK-960  |  JAK-IN-17  |  (E/Z)-Zotiraciclib  |  Rigosertib sodium  |  JAK-IN-10  |  PCI 29732  |  (3R,4S)-Tofacitinib  |  JAK3/BTK-IN-6  |  Tyk2-IN-5  |  Pirtobrutinib  |  Brevilin A  |  CNX-500  |  Broussonin E  |  Itacnosertib  |  BTK inhibitor 17  |  RO8191  |  Axltide  |  Fosifidancitinib  |  Remibrutinib  |  PLK1/BRD4-IN-1  |  RN486  |  JAK3-IN-6

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

货号: HY-18009

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。